Objectives. To review the fundamental concepts of pharmacogenetics and analyse how the
broad principles of this rapidly emerging field may influence the treatment of rheumatic …

Background: This systematic review summarizes the impact of pharmacogenetics on the
effect and safety of non-steroidal anti-inflammatory drugs (NSAIDs) and antidepressants …

CYP2C9 and CYP2C19 are important drug metabolizing enzymes and together metabolize
about 18% of currently available drugs. Some of the important groups of drugs that are …

The efficacy and safety of non-steroidal anti-inflammatory drugs (NSAIDs) may be
determined by the polymorphic nature of the CYP2C8, PTGS1 and PTGS2 genes. Objective …

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder that can lead to severe
joint damage and is often associated with a high morbidity and disability. Disease-modifying …

The current 'fixed-dosage strategy'approach to medicine, means there is much inter-
individual variation in drug response. Pharmacogenetics is the study of how inter-individual …

Human cytochrome P450 2C9 (CYP2C9) accounts for∼ 20% of hepatic total CYP content
and metabolizes∼ 15% clinical drugs such as phenytoin, S-warfarin, tolbutamide, losartan …

The Pharmacogenomics Journal (2003) 3, 6–7. doi: 10.1038/sj. tjp. 6500154 The
cytochrome P450 (CYP) enzymes play a crucial role in the metabolism of exogenous …

The application of pharmacogenetics in identifying single nucleotide polymorphisms (SNPs)
in DNA sequences that cause clinically significant alterations in drug-metabolizing enzyme …

Cytochrome P450 (CYP) 2C8 is responsible for the oxidative metabolism of many clinically
available drugs from a diverse number of drug classes (eg, thiazolidinediones, meglitinides …